Keyphrases
Adipose-derived Stromal Cells
100%
Mesenchymal Stromal Cells
76%
Allogeneic
39%
Mesenchymal Stem Cell Therapy
29%
Ischemic Heart Failure
27%
Cell Treatment
22%
Human Mesenchymal Stem Cells (hMSCs)
22%
Randomized Placebo-controlled Trial
19%
Ischemic Heart Disease
18%
Cryopreserved
18%
Placebo
17%
Left Ventricular Ejection Fraction
17%
Intramyocardial Injection
16%
Adipose-derived Mesenchymal Stem Cells (ADMSCs)
15%
Vascular Endothelial Growth Factor
14%
Left Ventricular End-diastolic Volume (LVEDV)
14%
Clinical Application
14%
Culture Expansion
14%
Paracrine
13%
Human Platelet Lysate
13%
Angiogenesis
13%
Intramyocardial
13%
Adipokinetic Hormone
12%
Stem Cells
12%
Cellular Products
11%
Cardiology
11%
Rat Model
11%
Healthy Donors
11%
Heart Failure
10%
Head-and-neck Cancer
10%
Refractory Angina
10%
Mode of Action
10%
Between-group
10%
Heart Failure with Preserved Ejection Fraction (HFpEF)
10%
Chronic Ischemic Heart Disease
10%
Cryopreservation
9%
Placebo Groups
9%
Stromal Cell Therapy
9%
Cancer Patients
9%
Fetal Bovine Serum
9%
NODAGA
8%
Serum Deprivation
8%
Potency Assay
8%
Radiation-induced Xerostomia
8%
Juxtacrine
8%
Alginate Hydrogel
8%
Dry Eye
8%
Allogeneic Mesenchymal Stem Cells
8%
Safety Study
8%
Immunomodulatory
8%
Medicine and Dentistry
Adipose Tissue
75%
Stromal Cell
70%
Mesenchymal Stem Cell
60%
Placebo
42%
Heart Failure
37%
Heart Muscle Ischemia
30%
Cell Therapy
25%
Ischemic Heart Disease
23%
Heart Left Ventricle Ejection Fraction
21%
Stem Cell
13%
Xerostomia
13%
End-Systolic Volume
11%
Angina pectoris
10%
Cardiology
10%
Adipose-Derived Mesenchymal Stem Cell
10%
Head and Neck Cancer
9%
Mesenchymal Stem Cell Transplantation
9%
Adverse Event
9%
Positron Emission Tomography
8%
Copper 64
8%
Platelet Lysate
8%
Dry Eye
8%
Eye Disease
8%
New York Heart Association Class
8%
Bone Marrow Stromal Cell
8%
In Vitro
8%
Stem Cell Therapy
7%
Vasculotropin
7%
Magnetic Resonance Imaging
6%
Quality of Life
6%
Heart Function
6%
Symptom
5%
Cell Expansion
5%
Iron Oxide
5%
Ultrasmall Superparamagnetic Iron Oxide
5%
Phase II Trials
5%
Lacrimal Gland
5%
